1-6 of 6
Robert D. Toto
Close
Save search
Follow your search
Access your saved searches in your account
Would you like to receive an alert when new items match your search?
Close Modal
Sort by
Journal Articles

Efficacy of Dapagliflozin by Baseline Diabetes Medications: A Prespecified Analysis From the DAPA-CKD Study

Jelle M. Beernink, Frederik Persson, Niels Jongs, Gozewijn D. Laverman, Glenn M. Chertow, John J.V. McMurray, Anna Maria Langkilde, Ricardo Correa-Rotter, Peter Rossing, C. David Sjöström, Robert D. Toto, David C. Wheeler, Hiddo J.L. Heerspink
Journal: Diabetes Care
Diabetes Care 2023;46(3):602–607
https://doi.org/10.2337/dc22-1514
Published: 20 January 2023
View article titled, Efficacy of Dapagliflozin by Baseline Diabetes Medications: A Prespecified Analysis From the DAPA-CKD Study
Open the PDF for Efficacy of Dapagliflozin by Baseline Diabetes Medications: A Prespecified Analysis From the DAPA-CKD Study in another window
Journal Articles

Urinary Proteomics Identifies Cathepsin D as a Biomarker of Rapid eGFR Decline in Type 1 Diabetes

Christine P. Limonte, Erkka Valo, Viktor Drel, Loki Natarajan, Manjula Darshi, Carol Forsblom, Clark M. Henderson, Andrew N. Hoofnagle, Wenjun Ju, Matthias Kretzler, Daniel Montemayor, Viji Nair, Robert G. Nelson, John F. O’Toole, Robert D. Toto, Sylvia E. Rosas, John Ruzinski, Niina Sandholm, Insa M. Schmidt, Tomas Vaisar, Sushrut S. Waikar, Jing Zhang, Peter Rossing, Tarunveer S. Ahluwalia, Per-Henrik Groop, Subramaniam Pennathur, Janet K. Snell-Bergeon, Tina Costacou, Trevor J. Orchard, Kumar Sharma, Ian H. de Boer, for the Kidney Precision Medicine Project
Journal: Diabetes Care
Diabetes Care 2022;45(6):1416–1427
https://doi.org/10.2337/dc21-2204
Published: 04 April 2022
View article titled, Urinary Proteomics Identifies Cathepsin D as a Biomarker of Rapid eGFR Decline in Type 1 Diabetes
Open the PDF for Urinary Proteomics Identifies Cathepsin D as a Biomarker of Rapid eGFR Decline in Type 1 Diabetes in another window
Journal Articles

Efficacy and Safety of Dapagliflozin by Baseline Glycemic Status: A Prespecified Analysis From the DAPA-CKD Trial

Frederik Persson, Peter Rossing, Priya Vart, Glenn M. Chertow, Fan Fan Hou, Niels Jongs, John J.V. McMurray, Ricardo Correa-Rotter, Harpreet S. Bajaj, Bergur V. Stefansson, Robert D. Toto, Anna Maria Langkilde, David C. Wheeler, Hiddo J.L. Heerspink
Journal: Diabetes Care
Diabetes Care 2021;44(8):1894–1897
https://doi.org/10.2337/dc21-0300
Published: 28 June 2021
View article titled, Efficacy and Safety of Dapagliflozin by Baseline Glycemic Status: A Prespecified Analysis From the DAPA-CKD Trial
Open the PDF for Efficacy and Safety of Dapagliflozin by Baseline Glycemic Status: A Prespecified Analysis From the DAPA-CKD Trial in another window
Journal Articles

Anemia, Diabetes, and Chronic Kidney Disease

Uzma Mehdi, MD, Robert D. Toto, MD
Journal: Diabetes Care
Diabetes Care 2009;32(7):1320–1326
https://doi.org/10.2337/dc08-0779
Published: 01 July 2009
View article titled, Anemia, Diabetes, and Chronic Kidney Disease
Open the PDF for Anemia, Diabetes, and Chronic Kidney Disease in another window
Journal Articles

Effect of Ruboxistaurin on Urinary Transforming Growth Factor-β in Patients With Diabetic Nephropathy and Type 2 Diabetes

Richard E. Gilbert, MD, PHD, Sandra A. Kim, MD, MSC, Katherine R. Tuttle, MD, George L. Bakris, MD, Robert D. Toto, MD, Janet B. McGill, MD, Douglas J. Haney, PHD, Darren J. Kelly, PHD, Pamela W. Anderson, MD
Journal: Diabetes Care
Diabetes Care 2007;30(4):995–996
https://doi.org/10.2337/dc06-2079
Published: 01 April 2007
View article titled, Effect of Ruboxistaurin on Urinary Transforming Growth Factor-β in Patients With Diabetic Nephropathy and Type 2 Diabetes
Open the PDF for Effect of Ruboxistaurin on Urinary Transforming Growth Factor-β in Patients With Diabetic Nephropathy and Type 2 Diabetes in another window
Journal Articles

The Effect of Ruboxistaurin on Nephropathy in Type 2 Diabetes

Katherine R. Tuttle, MD, George L. Bakris, MD, Robert D. Toto, MD, Janet B. McGill, MD, Kuolung Hu, MS, Pamela W. Anderson, MD
Journal: Diabetes Care
Diabetes Care 2005;28(11):2686–2690
https://doi.org/10.2337/diacare.28.11.2686
Published: 01 November 2005
View article titled, The Effect of Ruboxistaurin on Nephropathy in Type 2 Diabetes
Open the PDF for The Effect of Ruboxistaurin on Nephropathy in Type 2 Diabetes in another window